

MEDICAL POLICY

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

Original Issue Date (Created):	2/28/2012
Most Recent Review Date (Revised):	6/3/2020
Effective Date:	9/1/2020

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Endovascular stent grafts using devices approved by the U.S. Food and Drug Administration may be considered **medically necessary** in the following situations:

- Descending thoracic aortic aneurysms used according to the FDA-approved specifications (see Policy Guidelines section).
- Acute, complicated (organ or limb ischemia or rupture) Type B thoracic aortic dissection.
- Traumatic descending aortic tears or rupture

Endovascular stent grafts are considered **investigational** for the treatment of descending aortic disorders that do not meet the above criteria, including but not limited to uncomplicated aortic dissection as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Endovascular stent grafts are considered **investigational** for the treatment of ascending aortic disorders, including but not limited to thoracic aortic arch aneurysms as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Policy Guidelines

Endograft placement relies on non-aneurysmal aortic segments proximal and distal to the aneurysm and/or dissection for anchoring, and a maximal graft diameter that varies by device. The GORE TAG® endoprosthesis is approved by the U.S. Food and Drug Administration (FDA) for “≥2 cm non-aneurysmal aorta proximal and distal to the aneurysm” and an “aortic inner diameter of 23–37 mm.” The Talent™ Thoracic Stent Graft System is approved by the FDA for

MEDICAL POLICY

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

“non-aneurysmal aortic proximal and distal neck lengths ≥ 20 mm” and “non-aneurysmal aortic diameter in the range of 18–42 mm.” The Zenith TX2® device is approved by the FDA for non-aneurysmal aortic segments “of at least 25 mm in length” and “diameter measured outer wall to outer wall of no greater than 38 mm and no less than 24 mm.”

Cross-reference:

MP-1.090 Endovascular Grafts for Abdominal Aortic Aneurysms

II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital BlueCross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Benefit Brochure for information on ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA

<https://www.fepblue.org/benefit-plans/benefit-plans-brochures-and-forms>

Note - The Federal Employee Program (FEP) Service Benefit Plan does not have a medical policy related to these services.*

III. DESCRIPTION/BACKGROUND

[TOP](#)

Thoracic Aortic Aneurysms

Aortic aneurysms are arterial dilations associated with age, atherosclerosis, and hypertension, as well as some congenital connective tissue disorders. The likelihood of significant sequelae from aortic aneurysm depends on the location, size, and underlying disease state. Left untreated, these aneurysms tend to enlarge over time, increasing the risk of rupture or dissection. Of greatest concern is the tendency for aortic aneurysms to rupture, with severe consequences including death. Another significant adverse occurrence of aortic aneurysm is aortic dissection, in which an intimal tear permits blood to enter the potential space between the intima and the muscular wall of the aorta. Stable dissections may be managed medically; however, dissections that impinge on the true lumen of the aorta or occlude branching vessels are a surgical emergency.

Treatment

Indications for the elective surgical repair of aortic aneurysms are based on estimates of the prognosis of the untreated aneurysm balanced against the morbidity and mortality of the intervention. The prognosis of thoracic aortic aneurysm (TAA) is typically reported in terms of the risk of rupture according to size and location, (i.e., the ascending or descending or

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

thoracoabdominal aorta). While several studies have estimated the risk of rupture of untreated aneurysms, these studies have excluded patients who underwent surgical repair; therefore, the true natural history of thoracic aneurysms is unknown. Clouse et al (1998) performed a population-based study of TAA diagnosed in Olmstead County, Minnesota, between 1980 and 1994. A total of 133 patients were identified; the primary clinical end points were cumulative rupture risk, rupture risk as a function of aneurysm size, and survival. The cumulative risk of rupture was 20% after 5 years. The 5-year risk of rupture as a function of aneurysm size at recognition was 0% for aneurysms less than 4 cm in diameter, 16% for those 4 to 5.9 cm, and 31% for aneurysms 6 cm or more. Interestingly, 79% of the ruptures occurred in women. Davies et al (2002) reported on the yearly rupture or dissection rates in 721 patients with TAA. A total of 304 patients were dissection-free at presentation; their natural history was followed for rupture, dissection, and death. Patients were excluded from analysis once the operation occurred. Not surprisingly, the authors reported that aneurysm size had a profound impact on outcomes. For example, based on their modeling, a patient with an aneurysm exceeding 6 cm in diameter could expect a yearly rate of rupture or dissection of at least 6.9% and a death rate of 11.8%. In a previous report, the authors suggested surgical intervention of a descending aorta aneurysm if its diameter measured 6.5 cm.

Surgical mortality and morbidity are typically subdivided into emergency and elective repair, with a focus on the incidence and risk of spinal cord ischemia, considered of the most devastating complications, resulting in paraparesis or paraplegia. The operative mortality of surgical repair of aneurysm of the descending and thoracoabdominal aorta is estimated at 6% to 12% and 10% to 15%, respectively, while mortality associated with emergent repair is considerably higher. In elective cases, predictors of operative mortality include renal insufficiency, increasing age, symptomatic aneurysm, presence of dissection, and other comorbidities (eg, cardiopulmonary or cerebrovascular disease). The risk of paraparesis or paraplegia is estimated at 3% to 15%. Thoracoabdominal aneurysms, larger aneurysms, presence of dissection, and diabetes are predictors of paraplegia. A number of surgical adjuncts have been explored to reduce the incidence of spinal cord ischemia, including distal aortic perfusion, cerebrospinal fluid drainage, hypothermia with circulatory arrest, and evoked potential monitoring. However, the optimal protective strategy is still uncertain.

This significant mortality and makes definitive patient selection criteria for repair of thoracic aneurysms difficult. Several authors have recommended an individual approach based on balancing the patients' calculated risk of rupture with their anticipated risk of postoperative death or paraplegia. However, in general, surgical repair is considered in patients with adequate physiologic reserve when the thoracic aneurysm measures from 5.5 to 6 cm in diameter or in patients with smaller symptomatic aneurysms.

MEDICAL POLICY

POLICY TITLE	ENDOASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

Thoracic Aortic Dissection

Aortic dissection can be subdivided into type A, which involves the aortic arch, and type B, which is confined to the descending aorta. Dissections are usually treated surgically, while type B dissections are usually treated medically, with surgery indicated for serious complications, such as visceral ischemia, impending rupture, intractable pain, or sudden reduction in aortic size. Dissections associated with obstruction and ischemia can also be subdivided into an obstruction caused by an intimal tear at branch vessel orifices, or by compression of the true lumen by the pressurized false lumen.

Treatment

Type A dissections are usually treated surgically, while type B dissections are usually treated medically, with surgery indicated for serious complications, such as visceral ischemia, impending rupture, intractable pain, or sudden reduction in aortic size. It has been proposed that endovascular therapy can repair the latter group of dissections by redirecting flow into the true lumen. The success of endovascular stent grafts of abdominal aortic aneurysms has created interest in applying the same technology to the aneurysms and dissections of the descending or thoracoabdominal aorta.

As noted, type A dissections (involving the ascending aorta) are treated surgically. There is more controversy regarding the optimal treatment of type B dissections (i.e., limited to the descending aorta). In general, chronic, stable type B dissections are managed medically, although some surgeons have recommended a more aggressive approach for younger patients in otherwise good health. When serious complications arise from a type B dissection (i.e., shock or visceral ischemia), surgical intervention is usually indicated. Although there is an estimated 50% one-year survival rate in those treated with an open surgical procedure, it is not clear whether that rate is any better or worse for those treated medically. The advent of stent grafting, with the potential of reducing the mortality and of an open surgical procedure, may further expand the number of patients considered for surgical intervention.

Thoracic Aortic Rupture

Rupture of the thoracic aorta is a life-threatening emergency that is nearly always fatal if untreated. Thoracic artery rupture can result from a number of factors. Aneurysms can rupture due to progressive dilatation and pressure of the aortic wall. Rupture can also result from traumatic injury to the aorta, such as occurs with blunt chest trauma. Penetrating injuries that involve the aorta can also lead to rupture. Penetrating ulcers can occur in widespread atherosclerotic disease and lead to aortic rupture.

POLICY TITLE	ENDOASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

Treatment

Emergent repair of thoracic artery rupture is indicated in many cases in which there is free bleeding into the mediastinum and/or complete transection of the aortic wall. In some cases of aortic rupture, where the aortic media and adventitia are intact, watchful waiting with delayed surgical intervention is a treatment option. With the advent of thoracic endovascular aneurysm repair (TEVAR), the decision making for intervention may be altered, because there may be a greater tendency to intervene in borderline cases due to the potential for fewer adverse events with TEVAR.

Thoracic Endovascular Aneurysm Repair

TEVAR is an alternative to open surgery. TEVAR has been proposed for prophylactic treatment of aneurysms that meet criteria for surgical intervention, as well as for patients in need of emergency surgery for rupture or complications related to dissection. The standard open surgery technique for TAA is open operative repair with graft replacement of the diseased segment. This procedure requires lateral thoracotomy, use of cardiopulmonary bypass, lengthy surgical procedures, and is associated with a variety of peri- and postoperative complications, with spinal cord ischemia considered the most devastating.

TEVAR is performed through a small groin incision to access the femoral artery, followed by delivery of catheters across the diseased portion of the aorta. A tubular stent graft composed of fabric and metal is then deployed under fluoroscopic guidance. The stent graft is then fixed to the proximal and distal portions of the aorta. Approximately 15% of patients do not have adequate femoral access; for them, the procedure can be performed using a retroperitoneal approach.

Potential complications of TEVAR are bleeding, vascular access site complications, spinal cord injury with paraplegia, renal insufficiency, stroke, and cardiopulmonary complications. Some of these complications are similar to those encountered with open repair (eg, paraplegia, cardiopulmonary events), and others are unique to TEVAR (eg, access site complications).

Outcome Measures

Controlled trials of specific patient groups treated with specific procedures are required to determine whether endovascular approaches are associated with equivalent or improved outcomes compared with surgical repair. For patients who are candidates for surgery, open surgical resection of the aneurysm with graft replacement is considered the criterion standard for treatment of aneurysms or dissections. Some patients who would not be considered candidates for surgical therapy (due to unacceptable risks) might be considered candidates for an endovascular graft. In this situation, the outcomes of endovascular grafting should be compared with optimal medical management. Comparative mortality rates are of high concern, as are the rates of serious complications such as the incidence of spinal cord ischemia.

POLICY TITLE	ENDOASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

REGULATORY STATUS

A number of endovascular grafts are approved for use in thoracic aortic aneurysms (TAAs; see Table 1)

Table 1. Endovascular Grafts Approved for Use in Thoracic Aortic Aneurysms

Device	Manufacturer	Date Approved	PMA No.
GORE TAG® Thoracic Endoprosthesis	W.L. Gore and Associates	Mar 2005	P040043
Zenith TX2® TAA Endovascular Graft	Cook Europe	May 2008	P070016
Zenith Alpha™ Thoracic Endovascular Graft	Cook	Sep 2015	P140016
Talent™ Thoracic Stent Graft System	Medtronic Vascular	Jun 2008	P070007
Relay® Thoracic Stent-Graft with Plus Delivery System	Bolton Medical	Sep 2012	P110038
Valiant™ Thoracic Stent Graft with the Captivia® Delivery System	Medtronic Vascular	Apr 2011	P100040

PMA: premarket approval.

The Gore TAG® Thoracic Endoprosthesis is indicated for endovascular repair of aneurysms of the descending thoracic aorta. Use of this device requires patients to have adequate iliac/femoral access, aortic inner diameter in the range of 23 to 37 mm, and 2 cm or more nonaneurysmal aorta proximal and distal to the aneurysm. In January 2012, the Food and Drug Administration expanded the indication for the Gore TAG® system to include isolated lesions of the thoracic aorta. Isolated lesions refer to aneurysms, ruptures, tears, penetrating ulcers, and/or isolated hematomas, but do not include dissections. Indicated aortic inner diameter is 16 to 42 mm, with 20 mm or more of nonaneurysmal aortic distal and proximal to the lesion.

The Zenith TX2® TAA Endovascular Graft was approved by FDA through the premarket approval (PMA) process for the endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta. Indicated aortic inner diameter ranges from 24 to 38 mm.

The Talent™ Thoracic Stent Graft System was approved by FDA through the PMA process for the endovascular repair of fusiform and saccular aneurysms or penetrating ulcers of the descending thoracic aorta. Indicated aortic inner diameter is in the range of 18 to 42 mm.

The Relay® Thoracic Stent-Graft with Plus Delivery System was approved by FDA through the PMA process for the endovascular repair of fusiform aneurysms and saccular aneurysms or penetrating atherosclerotic ulcers in the descending thoracic aorta in patients having appropriate anatomy, including:

MEDICAL POLICY

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

- Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories
- Nonaneurysmal aortic neck diameter in the range of 19 to 42 mm
- Nonaneurysmal proximal aortic neck length between 15 and 25 mm and nonaneurysmal distal aortic neck length between 25 and 30 mm depending on the diameter stent graft required.

The Valiant™ Thoracic Stent Graft with the Captivia® Delivery System was approved by FDA for isolated lesions of the thoracic aorta. Isolated lesions refer to aneurysms, ruptures, tears, penetrating ulcers, and/or isolated hematomas, but not dissections. Indicated aortic diameter is 18 to 42 mm for aneurysms and penetrating ulcers, and 18 to 44 mm for blunt traumatic injuries. In January 2014, FDA expanded the indication for this graft and delivery system to include all lesions of the descending thoracic aorta, including type B dissections. The Valiant™ graft is intended for the endovascular repair of all lesions of the descending aorta in patients having appropriate anatomy, including:

- Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
- Nonaneurysmal aortic diameter in the range of 18 to 42 mm (fusiform and saccular aneurysms/penetrating ulcers), 18 to 44 mm (blunt traumatic aortic injuries [BTAI]), or 20 to 44 mm (dissections) and;
- Nonaneurysmal aortic proximal and distal neck lengths 20 mm or more (fusiform and saccular aneurysms/penetrating ulcers), and landing zone 20 mm or more proximal to the primary entry tear (BTAI, dissection). The proximal extent of the landing zone must not be dissected.

The expanded approval was based on the Medtronic Dissection Trial (NCT01114724), a prospective, nonrandomized study that evaluated the performance of the Valiant™ stent graft for acute, complicated type B dissection, which included 50 patients enrolled at 16 sites.

Other devices are under development and, in some situations, physicians have adapted other commercially available stent grafts for use in the thoracic aorta.

FDA product code: MIH

IV. RATIONALE

[TOP](#)

SUMMARY OF EVIDENCE

For individuals who have type B (descending) thoracic aortic aneurysms who receive endovascular repair, the evidence includes nonrandomized comparative studies and systematic reviews. Relevant outcomes are overall survival, morbid events, and treatment-related mortality

MEDICAL POLICY

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

and morbidity. The available nonrandomized comparative studies have consistently reported reduced short-term mortality and morbidity compared with surgical repair. Although these types of studies are subject to selection bias and other methodologic limitations, the consistency of the findings of equivalent or reduced short-term mortality and fewer early complications across populations with different characteristics supports the conclusion that TEVAR is a safer procedure in the short term. The likely short-term benefits of TEVAR are mitigated by less favorable longer term outcomes, but longer term mortality appears to be roughly similar for patients undergoing TEVAR or open surgery. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have type B (descending) aortic dissections who receive endovascular repair, the evidence includes RCTs, systematic reviews, and nonrandomized comparative studies. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. For acute uncomplicated type B dissections, an RCT has reported short-term improvements in aortic remodeling and a decreased risk of aortic dilation and rupture in patients treated with TEVAR compared with best medical management. However, this trial was underpowered to evaluate mortality differences, and limitations included a high TEVAR failure rate based on imaging follow-up. For acutely complicated type B dissections, there are no RCTs. Short- and intermediate-term results from a systematic review of observational studies that compared TEVAR with open surgery has suggested a benefit for TEVAR in complicated (organ or limb ischemia or rupture) type B dissection. However, this evidence is limited by selection bias and baseline differences between groups and therefore is not definitive on the efficacy of TEVAR vs open surgery. For chronic type B dissections, evidence from an RCT did not demonstrate short-term outcome benefits associated with TEVAR; however, after more than 5 years of follow-up, TEVAR was associated with a survival benefit beginning 2 years postprocedure. Additional evidence from high-quality trials is needed to determine whether TEVAR improves outcomes for patients having type B aortic dissections. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have traumatic descending aortic tears or rupture who receive endovascular repair, the evidence includes nonrandomized comparative studies and systematic reviews. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. For traumatic thoracic aortic injury and rupture, nonrandomized comparative data have suggested a benefit for TEVAR in reducing periprocedural mortality and morbidity. Although it is expected that RCTs will be difficult to conduct for this indication (due to its emergent nature), the risks of bias in the available nonrandomized studies are high, raising uncertainty about results. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have ascending aortic disorders who receive endovascular repair, the evidence includes small case series. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. For patients with ascending aortic pathologies,

MEDICAL POLICY

POLICY TITLE	ENDOASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

including dissections, aneurysms, and other disorders, the evidence on the use of TEVAR is limited to small series that have assessed heterogeneous patient populations. The evidence is insufficient to determine the effects of the technology on health outcomes.

V. DEFINITIONS

[TOP](#)

AORTA is the largest artery in the body, originating from the left ventricle of the heart and extending down to the abdomen, where it branches off into two smaller arteries (the common iliacs). The aorta distributes oxygenated blood to all parts of the body through the systemic circulation. It is usually divided into five segments/sections:

- Ascending aorta—the section between the heart and the arch of aorta
- Arch of aorta—the peak part that looks somewhat like an inverted "U"
- Descending aorta—the section from the arch of aorta to the point where it divides into the common iliac arteries
 - Thoracic aorta—the half of the descending aorta above the diaphragm
 - Abdominal aorta—the half of the descending aorta below the diaphragm

STENT refers to any material or device used to hold tissue in place, to maintain open blood vessels, or to provide support for a graft or anastomoses while healing is taking place.

THORACIC refers to the chest or thorax.

VI. BENEFIT VARIATIONS

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital BlueCross. Members and providers should consult the member's health benefit plan for information or contact Capital BlueCross for benefit information.

VII. DISCLAIMER

[TOP](#)

Capital BlueCross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical

MEDICAL POLICY

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

policy and a member’s benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member’s plan of benefits, please contact Capital BlueCross’ Provider Services or Member Services. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[TOP](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

CPT Codes®								
33880	33881	33883	33884	33886	33889	34812	75956	75957
75958	75959							

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

ICD-10-CM Diagnosis Codes	Description
I71.01	Dissection of thoracic aorta
I71.03	Dissection of thoracoabdominal aorta
I71.1	Thoracic aortic aneurysm, ruptured
I71.2	Thoracic aortic aneurysm, without rupture
I71.5	Thoracoabdominal aortic aneurysm, ruptured
I71.6	Thoracoabdominal aortic aneurysm, without rupture

IX. REFERENCES

[TOP](#)

1. *Abraha I, Romagnoli C, Montedori A, et al. Thoracic stent graft versus surgery for thoracic aneurysm. Cochrane Database Syst Rev. Jun 06 2016(6):CD006796. PMID 27265222*
2. *Appoo JJ, Herget EJ, Pozeg ZI, et al. Midterm results of endovascular stent grafts in the proximal aortic arch (zone 0): an imaging perspective. Can J Cardiol. Jun 2015;31(6):731-737. PMID 25882336*
3. *Blue Cross Blue Shield Association Medical Policy Reference Manual. 7.01.86 Endovascular Stent Grafts for Disorders of the Thoracic Aorta. May 2018.*

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

4. Boufi M, Patterson BO, Loundou AD, et al. Endovascular Versus Open Repair for Chronic Type B Dissection Treatment: A Meta-Analysis. *Ann Thorac Surg.* May 2019; 107(5): 1559-1570. PMID 30481516
5. Brunkwall J, Kasprzak P, Verhoeven E, et al. Endovascular repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: 1 year results of the ADSORB trial. *Eur J Vasc Endovasc Surg.* Sep 2014;48(3):285-291. PMID 24962744
6. Clouse WD, Hallett JW, Jr., Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population- based study. *JAMA.* Dec 9 1998;280(22):1926-1929. PMID 9851478
7. Coady MA, Rizzo JA, Hammond GL, et al. Surgical intervention criteria for thoracic aortic aneurysms: a study of growth rates and complications. *Ann Thorac Surg.* Jun 1999;67(6):1922-1926; discussion 1953-1928. PMID 10391339
8. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg.* Jan 2002;73(1):17-27; discussion 27-18. PMID 11834007
9. Elkbuli A, Dowd B, Spano PJ, et al. Thoracic Endovascular Aortic Repair Versus Open Repair: Analysis of the National Trauma Data Bank. *J Surg Res.* Jan 2020; 245: 179-182. PMID 31421360
10. Estrera AL, Rubenstein FS, Miller CC, 3rd, et al. Descending thoracic aortic aneurysm: surgical approach and treatment using the adjuncts cerebrospinal fluid drainage and distal aortic perfusion. *Ann Thorac Surg.* Aug 2001;72(2):481-486. PMID 11515886
11. Estrera AL, Miller CC, 3rd, Huynh TT, et al. Neurologic outcome after thoracic and thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* Oct 2001;72(4):1225-1230; discussion 1230-1221. PMID 11603441
12. Fairman RM, Criado F, Farber M, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR trial. *J Vasc Surg.* Sep 2008;48(3):546-554. PMID 18572352
13. Fairman RM, Tucheck JM, Lee WA, et al. Pivotal results for the Medtronic Valiant Thoracic Stent Graft System in the VALOR II trial. *J Vasc Surg.* Nov 2012;56(5):1222-1231 e1221. PMID 22832267
14. Fattori R, Montgomery D, Lovato L, et al. Survival after endovascular therapy in patients with type B aortic dissection: a report from the International Registry of Acute Aortic Dissection (IRAD). *JACC Cardiovasc Interv.* Aug 2013;6(8):876-882. PMID 23968705
15. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *J Am Coll Cardiol.* Apr 6 2010;55(14):e27-e129. PMID 20359588

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

16. Huynh TT, Miller CC, 3rd, Estrera AL, et al. Thoracoabdominal and descending thoracic aortic aneurysm surgery in patients aged 79 years or older. *J Vasc Surg. Sep 2002;36(3):469-475. PMID 12218969*
17. Food and Drug Administration Summary of Safety and Effectiveness. Valiant Thoracic Stent Graft with the Captivia Delivery System. 2014; http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100040S012b.pdf. Accessed June 3, 2020.
18. Jonker FH, Trimarchi S, Verhagen HJ, et al. Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. *J Vasc Surg. Apr 2010;51(4):1026-1032. PMID 20347700*
19. Lee WA, Matsumura JS, Mitchell RS, et al. Endovascular repair of traumatic thoracic aortic injury: clinical practice guidelines of the Society for Vascular Surgery. *J Vasc Surg. Jan 2011;53(1):187-192. PMID 20974523*
20. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. *J Vasc Surg. Jan 2005;41(1):1-9. PMID 15696036*
21. Makaroun MS, Dillavou ED, Wheatley GH, et al. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. *J Vasc Surg. May 2008;47(5):912-918. PMID 18353605*
22. Matsumoto AH, Angle JF, Secic M, et al. Secondary procedures following thoracic aortic stent grafting in the first 3 years of the VALOR test and VALOR II trials. *J Vasc Interv Radiol. May 2014;25(5):685-692 e685. PMID 24529546*
23. Matsumura JS, Melissano G, Cambria RP, et al. Five-year results of thoracic endovascular aortic repair with the Zenith TX2. *J Vasc Surg. Jul 2014;60(1):1-10. PMID 24636714*
24. Moulakakis KG, Mylonas SN, Dalainas I, et al. Management of complicated and uncomplicated acute type B dissection. A systematic review and meta-analysis. *Ann Cardiothorac Surg. May 2014;3(3):234-246. PMID 24967162*
25. Nienaber CA, Kische S, Akin I, et al. Strategies for subacute/chronic type B aortic dissection: the Investigation Of Stent Grafts in Patients with type B Aortic Dissection (INSTEAD) trial 1-year outcome. *J Thorac Cardiovasc Surg. Dec 2010;140(6 Suppl):S101-108; discussion S142-S146. PMID 21092774*
26. Nienaber CA, Kische S, Rousseau H, et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. *Circ Cardiovasc Interv. Aug 2013;6(4):407-416. PMID 23922146*
27. Pang D, Hildebrand D, Bachoo P. Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury. *Cochrane Database Syst Rev. Sep 25 2015;9(9):CD006642. PMID 26407315*
28. Rectenwald JE, Huber TS, Martin TD, et al. Functional outcome after thoracoabdominal aortic aneurysm repair. *J Vasc Surg. Apr 2002;35(4):640-647. PMID 11932656*

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

29. Roselli EE, Idrees J, Greenberg RK, et al. Endovascular stent grafting for ascending aorta repair in high-risk patients. *J Thorac Cardiovasc Surg.* Jan 2015;149(1):144-151. PMID 25312226
30. Safi HJ, Miller CC, 3rd, Subramaniam MH, et al. Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision. *J Vasc Surg.* Oct 1998;28(4):591-598. PMID 9786251
31. Safi HJ, Subramaniam MH, Miller CC, et al. Progress in the management of type I thoracoabdominal and descending thoracic aortic aneurysms. *Ann Vasc Surg.* Sep 1999;13(5):457-462. PMID 10466987
32. Scalea TM, Feliciano DV, DuBose JJ, et al. Blunt Thoracic Aortic Injury: Endovascular Repair Is Now the Standard. *J Am Coll Surg.* Apr 2019; 228(4): 605-610. PMID 30630086
33. Thrumurthy SG, Karthikesalingam A, Patterson BO, et al. A systematic review of mid-term outcomes of thoracic endovascular repair (TEVAR) of chronic type B aortic dissection. *Eur J Vasc Endovasc Surg.* Nov 2011;42(5):632-647. PMID 21880515
34. Ultee KHJ, Zettervall SL, Soden PA, et al. The impact of endovascular repair on management and outcome of ruptured thoracic aortic aneurysms. *J Vasc Surg.* Aug 2017;66(2):343-352 e341. PMID 28366304
35. Vallabhajosyula P, Gottret JP, Bavaria JE, et al. Endovascular repair of the ascending aorta in patients at high risk for open repair. *J Thorac Cardiovasc Surg.* Feb 2015;149(2 Suppl):S144-150. PMID 25218530
36. van Dongen EP, Schepens MA, Morshuis WJ, et al. Thoracic and thoracoabdominal aortic aneurysm repair: use of evoked potential monitoring in 118 patients. *J Vasc Surg.* Dec 2001;34(6):1035-1040. PMID 11743557
37. Webb TH, Williams GM. Thoracoabdominal aneurysm repair. *Cardiovasc Surg.* Oct 1999;7(6):573-585. PMID 10519663
38. Yamaguchi T, Nakai M, Sumita Y, et al. Editor's Choice - Endovascular Repair Versus Surgical Repair for Japanese Patients With Ruptured Thoracic and Abdominal Aortic Aneurysms: A Nationwide Study. *Eur J Vasc Endovasc Surg.* Jun 2019; 57(6): 779-786. PMID 30837104
39. Vallabhajosyula P, Gottret JP, Bavaria JE, et al. Endovascular repair of the ascending aorta in patients at high risk for open repair. *J Thorac Cardiovasc Surg.* Feb 2015;149(2 Suppl):S144-150. PMID 25218530
40. Blue Cross Blue Shield Association Medical Policy Manual. 7.01.86 Endovascular Stent Grafts for Disorders of the Thoracic Aorta. May 21, 2020

POLICY TITLE	ENDOVASCULAR STENT GRAFTS FOR DISORDERS OF THE THORACIC AORTA
POLICY NUMBER	MP-1.132

X. POLICY HISTORY

[Top](#)

MP 1.132	CAC 2/28/2012 Adopt BCBSA. Information related to endovascular stent grafts for thoracic aortic aneurysms was extracted from MP 1.090 Endovascular Repair of Aortic Aneurysms and this separate policy created. Added medically necessary statement for use with acute, complicated (organ or limb ischemia or rupture) Type B thoracic dissections. Treatment of aortic dissections was previously considered investigational.
	CAC 3/26/12 Consensus review. References updated but no changes to the policy statements. FEP variation revised to refer to the FEP medical policy manual. Policy title revised to Endovascular Stent Grafts for Disorders of the Thoracic Aorta. Background extensively rewritten.(Codes reviewed)
	CAC 1/28/14 Minor review. Medically necessary indication added for acute rupture of the thoracic aorta. Rationale section added. Changed title to Endovascular Stent Grafts for Disorders of the Thoracic Aorta (formerly Endovascular Stent Grafts for Thoracic Aortic Aneurysms or Dissections).
	CAC 1/27/15 Consensus. No change to policy statements. References and rationale updated. Codes reviewed.
	CAC 1/26/16 Consensus review. No change to policy statements. References and rationale updated. Coding reviewed.
	CAC 11/29/16 Consensus review. No change to policy statements. References and rationale updated. Variation reformatting. Coding reviewed/updated.
	CAC 12/19/17 Consensus review. No changes to the policy statements. Background, references, and rationale updated. Coding reviewed.
	10/4/18 Consensus review. Policy statements edited for clarity; intent of statements unchanged. Rationale revised. References updated.
	7/15/19 Consensus review. No changes to the policy statements. References and table updated.
	6/4/2020 Consensus Review. No changes to policy statement. References reviewed and updated. Coding reviewed, no changes. FEP variation updated.

[Top](#)

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.